Sanofi and Regeneron’s Praluent may still not be cost effective compared to other cholesterol-lowering drugs despite a recent price cut, a new study has claimed. The drug's high price point has ...

Additionally, Praluent was associated with a 15% lower risk of death from any cause, which occurred in 334 (3.5%) of patients in the Praluent group and 392 (4.1%) of patients in the placebo group.

They weren’t very effective; on a statin, my total cholesterol was still 226 mg/dL. Without medicine, it was 310 mg/dL. When I was put on Praluent by injection once a month, my cholesterol went down ...